Fibromyalgia - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 83 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Fibromyalgia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Fibromyalgia - Pipeline Review, H2 2014', provides an overview of the Fibromyalgia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fibromyalgia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Fibromyalgia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Fibromyalgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fibromyalgia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fibromyalgia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Fibromyalgia Overview 8
Therapeutics Development 9
Pipeline Products for Fibromyalgia - Overview 9
Pipeline Products for Fibromyalgia - Comparative Analysis 10
Fibromyalgia - Therapeutics under Development by Companies 11
Fibromyalgia - Therapeutics under Investigation by Universities/Institutes 13
Fibromyalgia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Fibromyalgia - Products under Development by Companies 17
Fibromyalgia - Products under Investigation by Universities/Institutes 18
Fibromyalgia - Companies Involved in Therapeutics Development 19
Collegium Pharmaceutical, Inc. 19
Concert Pharmaceuticals, Inc. 20
Daiichi Sankyo Company, Limited 21
Eli Lilly and Company 22
Merck & Co., Inc. 23
Pfizer Inc. 24
Sumitomo Dainippon Pharma Co., Ltd. 25
SWITCH Biotech LLC 26
Tonix Pharmaceuticals Holding Corp. 27
Fibromyalgia - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
BCIBUFP-004 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
C-10291 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
droxidopa - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
duloxetine hydrochloride DR - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
IMC-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
milnacipran hydrochloride - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
mirogabalin - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
mirtazapine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
naltrexone - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
pregabalin CR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PRTT-200 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SWT-06101 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
TD-9855 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
TNX-102 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Fibromyalgia - Recent Pipeline Updates 58
Fibromyalgia - Dormant Projects 73
Fibromyalgia - Discontinued Products 74
Fibromyalgia - Product Development Milestones 75
Featured News & Press Releases 75
Sep 29, 2014: Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia 75
May 12, 2014: Tonix Pharmaceuticals Completes Enrollment in BESTFIT Trial of TNX-102 SL for Fibromyalgia 76
Apr 30, 2014: Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia 76
Dec 10, 2013: Tonix Pharmaceuticals Announces the Enrollment of Completers From the BESTFIT Trial Into a 12-Month Open-Label Extension Study 77
Nov 26, 2013: Tonix Pharmaceuticals to Present at the Oppenheimer Healthcare Conference 78
Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013 78
Sep 16, 2013: Tonix Pharmaceuticals Initiates Enrollment in Phase 2b BESTFIT Trial of TNX-102 SL in Fibromyalgia Patients 79
Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome 79
Mar 11, 2013: Tonix Completes Pre-Phase III Meeting With FDA For TNX-102 SL In Fibromyalgia 80
Dec 04, 2012: Theravance Initiates Phase II Study With TD-9855 For Treatment Of Fibromyalgia 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83

List of Tables
Number of Products under Development for Fibromyalgia, H2 2014 9
Number of Products under Development for Fibromyalgia - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Fibromyalgia - Pipeline by Collegium Pharmaceutical, Inc., H2 2014 19
Fibromyalgia - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 20
Fibromyalgia - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 21
Fibromyalgia - Pipeline by Eli Lilly and Company, H2 2014 22
Fibromyalgia - Pipeline by Merck & Co., Inc., H2 2014 23
Fibromyalgia - Pipeline by Pfizer Inc., H2 2014 24
Fibromyalgia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 25
Fibromyalgia - Pipeline by SWITCH Biotech LLC, H2 2014 26
Fibromyalgia - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
Fibromyalgia Therapeutics - Recent Pipeline Updates, H2 2014 58
Fibromyalgia - Dormant Projects, H2 2014 73
Fibromyalgia - Discontinued Products, H2 2014 74